Clinical Trial: A Study of the Novel Drug Dimebon in Patients With Huntington's Disease
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: A Multi-Center, Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study of Dimebon in Subjects With Huntington's Disease
Brief Summary: This study will evaluate the safety of 3 months of Dimebon dosing and the efficacy of Dimebon in improving cognitive, motor, and overall function in subjects with Huntington's Disease.
Detailed Summary:
Sponsor: Medivation, Inc.
Current Primary Outcome: To assess the safety and tolerability of Dimebon during 3 months of treatment in subjects with Huntington's Disease. [ Time Frame: 90 days ]
Original Primary Outcome: To assess the safety and tolerability of Dimebon during 3 months of treatment in subjects with Huntington's Disease.
Current Secondary Outcome:
- To assess the impact of Dimebon during 3 months of treatment on cognitive, motor, and overall function in subjects with Huntington's Disease. [ Time Frame: 90 days ]
- To assess the pharmacokinetics of Dimebon. [ Time Frame: 90 days ]
Original Secondary Outcome:
- To assess the impact of Dimebon during 3 months of treatment on cognitive, motor, and overall function in subjects with Huntington's Disease.
- To assess the pharmacokinetics of Dimebon.
Information By: Medivation, Inc.
Dates:
Date Received: July 3, 2007
Date Started: July 2007
Date Completion:
Last Updated: May 16, 2015
Last Verified: May 2015
